DNP's New Touchless Transparent Screen Can Be Operated by Hand Movements
Amid increased awareness of hygiene and safety as the Covid-19 pandemic continues to spread around the world, Dai Nippon Printing Co., Ltd. (DNP) (TOKYO: 7912) has developed a new transparent display screen that can be operated in a touchless format, by merely moving a hand over a motion sensor. By removing the need to make direct contact with the cursor, the newly developed screen will be positioned as a countermeasure to the spread of Covid-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215006213/en/
[At left] Sensor unable to detect the operator’s hand [At right] Once the operator’s hand has been detected, the integrated LC light control film dims the screen making it possible to display clear images (Graphic: Business Wire)
https://www.youtube.com/watch?v=h5QKhThRtWw
A liquid crystal (LC) light control film is attached to a transparent screen facilitating a variety of video expressions on a single screen, from standard displays to augmented reality (AR) driven effects, including those where vivid images appear to hang in the air.
For further information about LC light control film, please visit:
https://www.dnp.co.jp/eng/news/detail/1191596_2453.html
For further information about transparent screens that can be used in bright location please visit:
https://www.dnp.co.jp/eng/news/detail/10158931_2453.html.
[Background]
As health and safety awareness grows, more users are calling for the development of products with antibacterial and antiviral functions, along with those that can be used in a touchless format.
At the same time, we have also recently seen a heightened focus on AR technology that supports consumer activities by imposing artificially created information over existing real world information. In answer to these dual developments, DNP has created a touchless display screen capable of giving expression to AR-driven spatial effects that enhance the immersive impact of presentations.
This has been achieved through the successful combination of, 1, a motion sensor that detects the operator’s movements, 2, an LC light control film that produces a clear image, and 3, a transparent screen that heightens the AR effect.
[Display Features]
- The in-built motion sensor detects the movements of users and operators, and by activating the LC light control film, which is integrated into the transparent screen, makes it possible to display clearer images.
- Bringing the palm of the hand closer to the screen activates the sensor, which causes the cursor to appear. The cursor can then be maneuvered in a touchless format via hand movements, including clicking on screen buttons to set actions into motion by bending the index finger towards the screen.
- DNP’s proprietary LC light control film leverages coating technology to achieve a precise coating of the LC. And, by controlling the direction of the LC using electrical power, it is possible to block or transmit light with high precision, enabling the display of diverse and clear images.
- The DNP transparent screen is produced by applying a precision lens to a large film substrate using advanced optical lens design technology and fine shaping technology.
- The background can be viewed by making the integrated LC light control film transparent then projecting an image upon it. In this way, it is possible to achieve an AR effect in which images appear to hand in the air.
[Looking Ahead]
We anticipate a variety of usage scenarios for the touchless transparent screen, such as in vending and ticket machines, along with uses as the reception desks at hotels and companies. In addition, DNP will further develop and propose LC light control films and transparent screens targeting touchless displays as a countermeasure against infectious diseases.
[About DNP]
DNP is one of the world’s largest comprehensive printing companies, providing a diverse portfolio of products and services to about 20,000 corporate clients worldwide. Since we were founded in 1876, we have consistently innovated new products and processes, and have successfully integrated proprietary printing and information technologies to branch out into various fields, including packaging, decorative materials, display components, and electronic devices. DNP continues to take on the challenge of new business fields, including those related to the environment, energy, and life sciences. Our aim is to become a principal provider of solutions to a variety of problems by developing and combining new technologies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215006213/en/
Contact information
Media contact:
Mr. Tamio Shinkai, IR and Public Relations Division
TEL: 813 6735-0101
E-mail: Shinkai-T@mail.dnp.co.jp
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
